Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Carbamazepine
Mawdsley-Brooks & Company Ltd
N03AF01
Carbamazepine
400mg
Oral tablet
Oral
No Controlled Drug Status
Caution - AMP level prescribing advised
BNF: 04080100
PACKAGE LEAFLET: INFORMATION FOR THE USER TEGRETOL ® RETARD 200 MG TABLETS TEGRETOL ® RETARD 400 MG TABLETS (CARBAMAZEPINE) The name of your medicine is Tegretol Retard 200 mg Tablets or Tegretol Retard 400 mg Tablets, and will be referred to as Tegretol Retard Tablets throughout this leaflet. WHAT YOU NEED TO KNOW ABOUT TEGRETOL RETARD TABLETS Your doctor has decided that you need this medicine to help treat your condition. PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR MEDICINE. IT CONTAINS IMPORTANT INFORMATION. KEEP THE LEAFLET IN A SAFE PLACE BECAUSE YOU MAY WANT TO READ IT AGAIN. If you have any other questions, or if there is something you don’t understand, please ask your doctor or pharmacist. This medicine has been prescribed for you. Never give it to someone else. It may not be the right medicine for them even if their symptoms seem to be the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1) What Tegretol Retard Tablets are and what they are used for 2) Things to consider before you start to take Tegretol Retard Tablets 3) How to take Tegretol Retard Tablets 4) Possible side effects 5) How to store Tegretol Retard Tablets 6) Further information 1) WHAT TEGRETOL RETARD TABLETS ARE AND WHAT THEY ARE USED FOR Tegretol Retard Tablets are specially formulated to release the active ingredient gradually. Carbamazepine, the active ingredient, can affect the body in several different ways. It is an anti-convulsant medicine (prevents fits), it can also modify some types of pain and can control mood disorders. Tegretol Retard Tablets are used • To treat some forms of epilepsy • To treat a painful condition of the face called trigeminal neuralgia • To help control serious mood disorders when some other medicines don’t work. 2) THINGS TO CONSIDER BEFORE YOU START TO TAKE TEGRETOL RETARD TABLETS SOME PEOPLE MUST NOT TAKE TEGRETOL RETARD TABLETS. TALK TO YOUR DOCT Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tegretol ® Prolonged Release 400mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active ingredient is 5H-dibenzo[b,f]azepine-5-carboxamide. Each coated tablet contains 400 mg carbamazepine Ph.Eur. 3 PHARMACEUTICAL FORM Prolonged Release Tablet. Tablets which are brownish-orange, oval, slightly biconvex, coated tablets with a score on each side. One side bears the imprint “ENE/ENE”, the other “CG/CG”. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Epilepsy - generalised tonic-clonic and partial seizures. Note: Tegretol is not usually effective in absences (petit mal) and myoclonic seizures. Moreover, anecdotal evidence suggests that seizure exacerbation may occur in patients with atypical absences. The paroxysmal pain of trigeminal neuralgia. For the prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Tegretol Prolonged Release is given orally, generally in the same total daily dose as conventional Tegretol dosage forms but usually in two divided doses. In a few patients when changing from other oral dosage forms of Tegretol to Tegretol Prolonged Release the total daily dose may need to be increased, particularly when it is used in polytherapy. When starting treatment with Tegretol Prolonged Release in monotherapy, 100-200mg once or twice daily is recommended. This may be followed by a slow increase in dosage until the best response is obtained, often 800-1200mg daily. In some instances, 1600mg or even 2000mg daily may be necessary. Tegretol Prolonged Release (either the whole or half divisible tablet as prescribed), should not be chewed but should be swallowed with a little liquid, before, during or between meals. The divisible tablet presentation enables flexibility of dosing to be achieved. Before deciding to initiate treatment, patients of Han Chinese and Thai origin should whenever possible be screened for HLA-B*1502 as this allele strongly predi Read the complete document